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Abstract:  The identification of TDP-43 as the major component of the pathologic 
inclusions in most forms of sporadic and familial frontotemporal lobar degeneration with 
ubiquitin-positive inclusions (FTLD-U) and amyotrophic lateral sclerosis (ALS) resolved 
a long-standing enigma concerning the nature of the ubiquitinated disease protein under 
these conditions. Anti-TDP-43 immunohistochemistry and the recent development of 
novel tools, such as phosphorylation-specific TDP-43 antibodies, have increased our 
knowledge about the spectrum of pathological changes associated with FTLD-U and 
ALS and moreover, facilitated the neuropathological routine diagnosis of these 
conditions. This review summarizes the recent advances in our understanding on the 
molecular neuropathology and pathobiology of TDP-43 in FTLD and ALS.  
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1. Introduction 
 
Frontotemporal lobar degeneration (FTLD), the second most common form of presenile dementia, 
refers to a clinically, genetically and neuropathologically heterogeneous group of neurodegenerative 
disorders. Clinically, FTLD is characterized by behavioural and/or language dysfunction [1]. In 
addition some affected individuals manifest with movement disorders such as parkinsonism or motor 
neuron disease (MND) [2, 3].  
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While the designation FTLD reflects the prominent frontal and temporal lobe degeneration, the 
characteristic lesions in the majority of FTLD brains are abnormal ubiquitinated protein inclusions. 
The protein tau has been identified as the protein building block in the inclusions in about 40% of 
FTLD cases, and its role in the pathogenesis of neurodegenerative diseases is well established 
especially after identification of mutation in the microtubule-associated protein tau (MAPT) gene in 
familial forms of FTLD [4]. However, the biochemical composition of the ubiquitinated inclusions in 
the most common pathological form of FTLD, namely FTLD-U, remained unknown until 2006, when 
the TAR-DNA binding protein 43 (TDP-43) was identified as the major disease protein in the majority 
of sporadic and familial FTLD-U cases [5, 6]. Subsequently, the ubiquitinated compact and skein-like 
inclusions, characteristic for amyotrophic lateral sclerosis (ALS) were also found to be composed of 
TDP-43 [5, 7], thereby providing strong evidence that both conditions are mechanistically linked and 
part of a clinico-pathological spectrum of disease, which can be subsumed as TDP-43   
proteinopathies [8, 9].  
The discovery of TDP-43 not only provided important new insight into the pathogenenic 
mechanisms underlying FTLD-U and ALS, but also dramatically improved the neuropathological 
characterization and diagnosis of these conditions. Moreover, it is anticipated that newly developed 
phosphorylation-specific TDP-43 antibodies [10, 11], allowing the highly sensitive detection of 
disease-modified TDP-43 species and the specific discrimination between TDP-43 in health and 
disease, will become the gold-standard in neuropathological routine diagnosis of neurodegenerative 
diseases. This review highlights the recent advances in our knowledge about the molecular 
neuropathology and pathobiology of TDP-43 in FTLD and ALS.  
 
2. Identification of TDP-43 as disease protein in FTLD-U and ALS 
 
Although extensive efforts have been made for many years in attempts to characterize the 
biochemical composition of the ubiquitinated inclusions (UBIs) in FTLD-U, they did not prove to be 
informative. Characterization of UBIs was complicated by the relative low abundance of UBIs, the 
uneven distribution of UBIs among different FTLD-U cases, and the non-amyloidogenic nature of 
UBIs as demonstrated by absence of staining with amyloid-binding dyes such as thioflavin S, Congo 
red, or silver stains. Therefore, an alternative immunologic approach was performed to identify the 
protein components in the ubiquitinated inclusions in FTLD-U [5, 12]. Briefly, protein extracts 
enriched for insoluble proteins were generated from postmortem FTLD-U brains and high molecular 
mass material (Mr>250 kD) was used to immunize mice in order to generate antibodies raised against 
proteins in UBIs. After screening of thousands of hybridoma supernatants by immunohistochemistry 
(IHC), novel monoclonal antibodies (mAbs) selectively labeling UBIs were successfully identified. 
Extensive protein analysis including two-dimensional SDS-PAGE identified protein spots ~25kDa 
specifically recognized by these mAbs in FTLD-U brains, but not in controls and other 
neurodegenerative diseases. Subsequently, the resulting peptides obtained by liquid chromatographic 
mass spectrometry were found to correspond to amino acid sequences in the C-terminal part of a 
protein known as TDP-43. Commercially available antibodies against TDP-43 consistently labeled the 
UBIs in sporadic and familial FTLD-U as well as sporadic ALS, but not the characteristic lesions in a 
variety of other neurodegenerative diseases, thereby confirming and validating TDP-43 as the major Int. J. Mol. Sci. 2009, 10                 
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protein component of UBIs in FTLD-U and ALS [5]. These findings were quickly confirmed   
by others [6].   
Most importantly, several disease-associated TDP-43 alterations with potential functional 
implications have been observed (Figure 1). Thus, TDP-43 inclusion body formation is accompanied 
by a dramatic change in the subcellular distribution of TDP-43 with complete lack of normal diffuse 
nuclear TDP-43 staining in inclusion-bearing cells [5]. Biochemical analysis of insoluble protein 
extracts isolated from affected FTLD-U and ALS tissue revealed a characteristic biochemical profile 
of TDP-43 with detection of disease-specific bands at ~25kDa, ~45 kDa and a smear of high-
molecular-mass proteins in addition to the normal 43 kDa band. Further analysis demonstrated that 
this profile is due to N-terminal truncation, hyperphosphorylation and ubiquitination of TDP-43 in 
FTLD-U and ALS [5]. The presence and extent of this pathologic signature in affected brain regions as 
well as spinal cord roughly corresponds with the density of TDP-43 positive inclusions detected   
by IHC.  
 
Figure 1. Neuropathology and biochemical alterations of TDP-43 in TDP-43-positive 
FTLD-U (“FTLD-TDP”). 
 
(a)  TDP-43 immunohistochemistry labels cytoplasmic inclusions in dentate granule cells in FTLD-
U. Note the dramatic loss of normal diffuse nuclear TDP-43 staining in inclusion-bearing cells.  
(b)  Immunoblot analysis of sarcosyl-insoluble protein fractions from TDP-43-positive FTLD-U 
shows highly characteristic biochemical signature with pathological bands ~25 kDa (*), ~45 kDa 
(**) and a high molecular smear (***) in addition to the normal TDP-43 ~ 43 kDa.  
 
The subsequent identification of 20 mutations to date in the gene TARDBP encoding for TDP-43 in 
ALS (see below) provides further strong evidence for a direct link between TDP-43 dysfunction and 
neurodegeneration.  
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3. TDP-43 pathology in sporadic and familial forms of FTLD-U  
 
As demonstrated in the initial reports and rapidly confirmed in numerous follow-up studies, TDP-
43 is a specific and sensitive marker to detect the characteristic inclusions (neuronal cytoplasmic 
inclusions (NCI), dystrophic neurites (DN) and neuronal intranuclear inclusions (NII)) in the majority 
of sporadic and familial FTLD-U cases, including familial FTLD-U forms with mutations in the 
progranulin (GRN) gene, valosin-containing protein (VCP) gene and those with linkage to 
chromosome 9p [5, 13-16]. The absence of binding partners of TDP-43, such as heterogeneous nuclear 
ribonucleoproteins A1, A2/B1 and C as well as survival motor neuron protein, in these inclusions 
further emphasizes the specificity of TDP-43 as marker for FTLD-U pathology [17]. Moreover, 
immunohistochemistry for TDP-43 also allowed the detection of previously unrecognized pathology in 
FTLD-U. These include sometimes widespread and abundant TDP-43-positive glial cytoplasmic 
inclusions (GCI) of presumed oligodendroglial lineage [18], more diffuse neuronal cytoplasmic 
“preinclusions” [19] and dystrophic neurites in the CA1 region in a subset of patients [16]. The 
majority of these types of lesions are typically ubiquitin-negative, explaining why they have not been 
recognized previously and furthermore arguing that ubiquitination of TDP-43 might be a late event in 
inclusion body formation.  
The recent development of new antibodies raised against specific TDP-43 epitopes and 
phosphorylated serine residues have further improved the detection sensitivity of TDP-43 pathology 
and understanding of inclusion body formation. Thus, immunohistochemical and biochemical analysis 
using C-terminal and N-terminal specific TDP-43 antibodies have demonstrated that the protein 
composition in NCIs in cortical brain regions is highly enriched for CTFs, while NCIs in the spinal 
cord contain more full-length TDP-43, thereby suggesting that inclusion body formation may be 
regionally different in TDP-43 poteinopathies [20].  
Antibodies raised against phosphorylated serine residues (S379, 403, 404, 409 and 410) of TDP-43 
further improve and facilitate the neuropathological assessment of TDP-43 pathology, as they only 
label abnormal TDP-43 in inclusions, but not the often strong physiological nuclear TDP-43 [10, 11]. 
 
3.1. Heterogeneity among TDP-43-positive FTLD-U cases  
 
While UBIs in FTLD-U are generally found in the frontal and temporal cortex as well as in dentate 
granule cells of the hippocampus in most FTLD-U cases, heterogeneity of FTLD-U pathology with 
respect to morphology, laminar distribution of ubiquitin and TDP-43 positive inclusions and relative 
proportion of DNs versus NCIs have been described in two independent studies, leading to the 
description of four distinct histological FTLD-U subtypes (subtypes 1-4) [12, 15, 21]. Representative 
images from TDP-43 staining patterns in distinct FTLD-U subtypes are shown in Figure 2 using the 
classification scheme described by Sampathu et al [12]. The characteristic pathological, clinical and 
genetic features among the four FTLD-U subtypes are summarized in Table 1. 
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Figure 2. Distinct histological subtypes of TDP-43-positive FTLD-U (“FTLD-TDP”). 
 
Immunohistochemistry with antibody against TDP-43 showing the characteristic cortical inclusions 
in the distinct FTLD-TDP subtypes (numbering according to Sampathu et al. [12]).  
 
Table 1. Heterogeneity among TDP-43-positive FTLD-U (“FTLD-TDP”). 
  type 1  type 2  type 3  type 4 
Pathology 
 
predominance 
of long neurites, 
NIIs absent - rare 
 
predominance 
of cytoplasmic 
inclusions, often 
preinclusions, 
NIIs absent - few 
small neurites and 
cytoplasmic 
inclusions, 
NIIs absent - 
abundant 
 
numerous NIIs and 
small neurites 
 
laminar 
distribution 
upper layer > lower  upper = lower layers upper layer >> lower  upper layer > lower
Glial 
inclusions 
 
absent - rare 
 
moderate - frequent moderate - frequent 
absent 
 
Clinical 
symptoms 
SD 
 
FTD often with 
MND 
FTD or PNFA 
 
IBMPFD 
 
Genetic 
defect in 
familial 
forms 
/ 
 
Chrom 9p 
 
GRN 
 
VCP 
 
Based on the pathological parameters of ubiquitin- and TDP-43-positive inclusions four distinct 
subtypes (numbering according to Sampathu et al. [12]) can be delineated. Notably, there is a 
striking association of histological subtypes with clinical and genetic parameters. Abbreviations: 
FTD, frontotemporal dementia; SD, semantic dementia; PNFA, progressive non-fluent aphasia; 
MND, motor neuron disease; IBMPFD, inclusion body myopathy associated with Paget’s disease of 
the bone and frontotemporal dementia. 
 
Briefly, subtype 1 histology (also known as subtype 2 in [21]) is characterized by an abundance of 
long neuritic profiles predominantly in superficial cortical laminae, with few or no NCIs or NIIs. Glial 
pathology is rare [18].  
In subtype 2 cases (also known as subtype 3 in [21]) the predominant inclusions are NCIs in both 
superficial and deep cortical layers with presence of few neurites, and few or no NIIs. An often more Int. J. Mol. Sci. 2009, 10                 
  
237
diffuse cytoplasmic staining of “preinclusions” is present. Motor neurons in the hypoglossal nuclei and 
ventral horn of the spinal cord with TDP-43 positive inclusions similar to that found in pure ALS cases 
are a common finding, correlating with the fact that patients with subtype 2 histology often represent 
with additional clinical signs of ALS/MND [21]. Moreover, subtype 2 is often associated with 
abundant glial pathology in affected cortical, brainstem and spinal cord regions [18]. 
Neuropathological and biochemical studies on seven cases with genetic linkage to chromosome 9p 
showed exclusively TDP-43 pathology with morphology and distribution pattern indicative of   
subtype 2 [15].  
The abundance of small neuritic profiles and NCIs, often ring-shaped, predominantly in the 
superficial cortical layers characterizes subtype 3 histology (also knows as subtype 1 in [21]). 
Especially in cases with positive family history, moderate numbers of lentiform NIIs can be found in 
affected cortical regions. Glial pathology is often present in affected cortical regions [18]. While there 
is variability in the extent of TDP-43 pathology among different brain regions, familial FTLD-U cases 
with GRN mutations exclusively show subtype 3 pathology [15, 22]. 
The characteristic neuropathological feature of subtype 4 pathology is the abundance of ubiquitin 
and TDP-43 positive NIIs and DNs with only few NCIs in affected cortical regions and the absence of 
inclusions in the hippocampal dentate granule cells [14, 23]. So far, all cases with subtype 4 pathology 
had VCP mutations and vice versa. 
The relevance of the heterogeneity of TDP-43 pathology among FTLD-U cases with respect to 
pathogenesis remains to be determined. However, the striking correlation of distinct histological 
subtypes with different genetic forms of familial FTLD-U [15] and its association with distinct clinical 
syndromes [13, 21] emphasizes the significance of this classification.  
 
3.2. Not all FTLD-U cases show TDP-43 pathology   
 
While the initial data suggested that all FTLD-U cases are indeed characterized by TDP-43 
pathology, recent follow-up papers on large series of FTLD-U cohorts have shown that there are some 
important exceptions. Thus, the ubiquitin-positive inclusions in the brains of family members from 
familial FTLD caused by a mutation in the charged multivesicular body protein (CHMP2B) gene do 
not contain TDP-43 [15, 24]. In addition, a significant number of sporadic FTLD-U cases have now 
been recognized with absence of TDP-43 pathology [15, 16, 25-27] and a detailed clinico-pathological 
description of these atypical FTLD-U (aFTLD-U) patients was provided in two recent studies on a 
total of 15 cases [25, 26]. aFTLD-U patients consistently presented with sporadic early-onset 
frontotemporal dementia with severe progressive behavioral and personality changes in the absence of  
aphasia or motor features. Besides TDP-43 negative, ubiquitin-positive NCIs, the most intriguing and 
most diagnostic pathological finding in aFTLD-U were unique ubiquitin-positive neuronal intranuclear 
inclusions. Based on the highly consistent clinical and neuropathological phenotype, it was suggested 
that aFTLD-U represents a new clinico-pathological disease entity.  
Since it emerged that the group currently designated as FTLD-U includes at least two distinct 
entities, a new nomenclature for FTLD was very recently recommended introducing the term FTLD-
TDP for TDP-43-positive FTLD-U and FTLD-UPS for those like aFTLD-U, were the ubiquitinated 
protein(s) remain to be identified [28].  Int. J. Mol. Sci. 2009, 10                 
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4. TDP-43 pathology in sporadic and familial ALS 
 
ALS, the most common form of adult-onset motor neuron disease, is characterized by a loss of 
upper and lower motor neurons, that results in progressive weakness, muscular wasting, and spasticity. 
About ~10 % of ALS cases are familial (fALS) and mutations in the Cu/Zn superoxide dismutase 
(SOD1) gene are thought to be the most common ones accounting for ~20% of fALS [29].  
After the initial report that the characteristic lesions obtained in remaining neurons in sporadic ALS 
(sALS), typically filamentous skeins or compact round inclusions, are composed of TDP-43, the role 
of TDP-43 in sALS versus fALS was further evaluated. Remarkably, while TDP-43 pathology is a 
consistent feature in all sALS and non-SOD1-fALS, there is neither histological nor biochemical 
evidence for TDP-43 pathology in SOD1-fALS cases [7, 30]. Together with the lack of TDP-43 
pathology in animal models with SOD1 mutations [31, 32], these data strongly imply that 
neurodegeneration in SOD1-fALS may results from a different mechanism than that underlying sALS 
and fALS due to mutations in genes other than SOD1.  
In addition to neuronal inclusions, GCIs are a consistent feature in sALS and non-SOD1-fALS [7]. 
TDP-43 immunohistochemistry also allowed the detection of more extensive and widespread 
pathology in extramotor regions in patients with ALS with and without dementia [33].  
The presence of TDP-43 pathology in ALS made TARDBP, the gene encoding TDP-43 a promising 
candidate for genetic screening. Initial screens in sporadic FTD and ALS, as well as familial FTD 
patients failed to identify mutations and no genetic variations could be identified as risk factor for 
developing FTD or ALS [34-36]. However, subsequent analysis of larger ALS cohorts have now led to 
the identification of 20 different mutations in 27 unrelated ALS patients (Figure 3), which were absent 
in healthy controls [37-44]. Twelve mutations were found in fALS following an autosomal dominant 
trait of inheritance, while others were reported only in sALS cases. Except the Y374X truncation 
mutation, all other TARDBP mutations are missense mutations mostly affecting highly conserved 
amino residues in the C-terminal region of TDP-43.  
 
Figure 3. ALS associated mutations in TDP-43. 
 
Schematic diagram of TDP-43 with characteristic functional domains of TDP-43 and sites of 
identified mutations in familial (fALS) and sporadic (sALS) amyotrophic lateral sclerosis. 
Abbreviations: RRM, RNA recognition motif; NLS: nuclear localization sequence; NES, nuclear 
export sequence.  Int. J. Mol. Sci. 2009, 10                 
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Neuropathological data are so far available for the G294A [37], G298S [42], and Q343R [45] 
TARDBP mutation, showing characteristic TDP-43 positive neuronal and glial inclusions in addition to 
motor neuron loss and presence of Bunina bodies.  
Thus far, the functional consequences of TARDBP mutations are unknown and need to be 
investigated in more detail in future studies.  
 
5. TDP-43 pathology in other neurodegenerative diseases 
 
Co-occurrence of distinct neurodegenerative disease lesions in the brains of patients with 
neurodegenerative disorders is an emerging theme in research in these conditions, as exemplified by 
the high frequency of Lewy body pathology in Alzheimer’s disease (AD) that was only recognized 
after the routine use of antibodies against α-synuclein. Analogous, TDP-43 immunohistochemistry 
now also enables the investigation of the co-occurrence of FTLD-U type TDP-43 pathology in the 
setting of other neurodegenerative disorders and indeed some degree of TDP-43 pathology has now 
been reported in a variety of other neurodegenerative diseases besides FTLD and ALS.  
Thus, TDP-43 pathology is a highly consistent finding in most cases of ALS-Parkinsonism-
dementia complex of Guam [46, 47]. Concomitant TDP-43 pathology has been reported in about 20-
30 % of patients with AD, in about 70% of patients with hippocampal sclerosis and in a smaller subset 
of cases with Lewy body diseases, Pick’s disease, corticobasal degeneration, agryrophilic grain disease 
and Huntington’s disease [48-54]. Unlike in FTLD, TDP-43 pathology in these conditions is mostly 
restricted to mesial temporal regions. TDP-43 immunoreactivity is often found in separate inclusions, 
or only partially colocalizes with characteristic lesions found in these diseases, such as neurofibrillary 
tangles [51, 53]. The clinical significance of additional TDP-43 in the setting of other 
neurodegenerative diseases is still uncertain and needs to be further examined in detailed clinico-
pathological studies.  
 
6. Biology and Pathobiology of TDP-43  
 
TDP-43 is a 414 amino acid protein encoded by the TARDBP gene on chromosome 1. It was first 
cloned as a human protein capable of binding to the transactive response DNA of human 
immunodeficiency virus type 1 [55], and later identified as part of a complex involved in splicing of 
the cystic fibrosis transmembrane conductance regulator gene [56] and the apolipoprotein A-II gene 
[57]. TDP-43 is highly conserved, ubiquitously expressed and predominantly localized to the nucleus 
under normal conditions. It consists of two RNA recognition motifs and a glycine-rich C-terminal 
region (Figure 3). The exon skipping and splicing inhibitory activity requires the C-terminal region of 
TDP-43 by interaction with other members of the heterogeneous nuclear ribonucleoprotein (hnRNP) 
family [58].  
In addition to its well characterized role in transcription and splicing regulation, more recent studies 
suggest that TDP might be involved in other cellular processes such as in microRNA biogenesis, 
apoptosis, cell division, mRNA stabilization and regulation of neuronal plasticity by acting as neuronal 
activity response factor [59-61]. Finally, TDP-43 may act as scaffold for nuclear bodies through 
interaction with survival motor neuron protein [62].  Int. J. Mol. Sci. 2009, 10                 
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The mechanistic aspects leading to accumulation of pathologic TDP-43 in cytoplasmic, neuritic, 
and nuclear inclusions and the functional consequences of TDP-43 accumulation are currently not well 
understood. The dramatic change in subcellular distribution of TDP-43 from the nucleus to the 
cytoplasm in affected cells in FTLD and ALS suggests that maybe loss of physiological nuclear TDP-
43 function in transcription and mRNA processing might play a pathogenic role. Alternatively, 
generation and sequestration of abnormal TDP-43 species such as C-terminal fragments and 
hyperphopshorylated TDP-43 enriched in inclusions might induce a toxic gain of function. Recent 
studies have shown that TDP-43 continuously shuttles between the nucleus and cytoplasm, a process 
partially regulated by nuclear localization signal (NLS) and nuclear export signal (NES) motifs 
[63,64]. Restricting TDP-43 from entering the nucleus by changing the NLS motif in cell culture 
systems is reported to lead to cytoplasmic TDP-43 aggregates, changes in the solubility of TDP-43 and 
sequestration of endogenous TDP-43, thereby leading to a depletion of nuclear TDP-43 [63]. Thus, 
perturbation of the normal shuttling of TDP-43 between nucleus and cytoplasm may predispose to 
both, the formation of cytoplasmic inclusions and loss of nuclear TDP-43. 
It is expected that elucidating the functional consequences of ALS-associated TARDBP mutations 
will provide us with important insights also into the disease mechanisms underlying sporadic ALS and 
FTLD-U. Currently discussed hypotheses are that TARDBP mutations might interfere with protein-
protein interaction, which might affect its nuclear transport or well-known transcriptional and splicing 
activities; or that TARDBP mutations might increase the aggregation tendency of TDP-43 perhaps due 
to increased phosphorylation [41-43].  
 
7. Conclusions  
 
TDP-43 is the major disease protein in most forms of FTLD-U and ALS, thereby providing strong 
evidence that both conditions are part of a clinico-pathological spectrum with common underlying 
pathomechanisms. The use of anti-TDP-43 antibodies have dramatically improved our knowledge 
about the spectrum of pathological changes underlying FTLD and ALS and it is highly recommended 
to implement immunohistochemistry for TDP-43 as routine stain in the neuropathological diagnostics 
of neurodegenerative diseases. Future research approaches, including development of novel cell 
culture and animal models, have to determine whether loss of function, toxic gain of function or a 
combination of both mechanisms contributes to cell death in TDP-43 proteinopathies.  
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